How ONL used iNebula to accelerate its Phase 2 trial
ONL discuss their collaboration on a recent Phase 2 rhegmatogenous retinal detachment (RRD) program. The panelists discuss the importance of partnering with a reading center that offers Voxeleron's iNebula platform - in particular for its real-time access to the image data as well as its AI-enabled endpoints. Featuring: Connie Change:…
Deep Learning-based Methods for In Vivo Corneal Microscopy
In Vivo Corneal Microscopy (IVCM) is a non-invasive imaging technique based on confocal imaging using near infrared light. Images acquired at the cornea generate a confocal “stack” of cellular level images that comprise different corneal layers. Because the cornea is the most densely innervated area of the human body, there…
How Allgenesis Evaluated Unique Endpoints to Advance its Phase
Allgenesis discuss their collaboration on a recent phase two study for diabetic macular edema (DME). The panelists highlight the importance of imaging and biomarkers in ophthalmology clinical trials and share their experiences working with Voxeleron's AI technology. Featuring: Tan Nguyen: Vice President of Research and Development at Allgenesis Biotherapeutics. Janet…
How Interoperability Drives Ophthalmic Clinical Trial Success for Voiant
Jason Slakter, MD and Hanna Coleman, MD of Voiant Clinical discuss how the unique interoperability of Voxeleron’s Orion platform helps drive ophthalmic clinical trial success. Want to learn more about Orion? Request a demo today or check out voxeleron.com/orion.
Voxeleron at ARVO 2024
Voxeleron at ARVO 2024 ARVO is upon us, and we look forward to visiting the pacific northwest again this year! It is, without doubt, a unique conference allowing for both formal and informal get-togethers, all with the shared objective of advancing ophthalmic research. In preparation for this, we’d like to…
How Allgenesis Evaluated Unique Endpoints to Advance its Phase 2A DME Study
Watch this exclusive on-demand webinar featuring Allgenesis Biotherapeutics as they unveil insights from their Phase 2A DME program. Learn how the trial was designed, and why working with Lexitas and Voxeleron facilitated efficient communication with sites and faster decision-making by management.
